Hologic, Inc. (HOLX)

Market Cap	13.05B
Revenue (ttm)	4.04B
Net Income (ttm)	744.00M
Shares Out	224.39M
EPS (ttm)	3.16
PE Ratio	18.43
Forward PE	13.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,386,810
Open	59.11
Previous Close	58.19
Day's Range	57.87 - 59.41
52-Week Range	55.89 - 84.67
Beta	0.83
Analysts	Buy
Price Target	84.17 (+44.57%)
Earnings Date	May 1, 2025

About HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginos...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 21, 1990
• Employees: 6,990
• Stock Exchange: NASDAQ
• Ticker Symbol: HOLX
• Website: https://www.hologic.com

Financial Performance

In 2024, Hologic's revenue was $4.03 billion, a decrease of -0.00% compared to the previous year's $4.03 billion. Earnings were $789.50 million, an increase of 73.14%.

Analyst Forecast

According to 14 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is $84.17, which is an increase of 44.57% from the latest price.

Price Target

$84.17

(44.57% upside)

Analyst Consensus: Buy